Aceragen, Inc. (ACGN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Exton, PA, アメリカ. 現CEOは John C. Taylor.
ACGN を有する IPO日 1996-01-25, 26 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $3.24M.
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
